References
[1] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW,
Carson AP et al. Heart disease and stroke statistics-2020 Update:
a report from the American Heart Association. Circulation
2020;141 :e139-e596.
[2] Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd,
Gentile F et al. 2020 ACC/AHA Guideline for the Management of
Patients With Valvular Heart Disease: Executive Summary: A Report of the
American College of Cardiology/American Heart Association Joint
Committee on Clinical Practice Guidelines. J Am Coll Cardiol
2021;77 :450-500.
[3] Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S,
Bauersachs J et al. 2021 ESC/EACTS Guidelines for the management
of valvular heart disease: Developed by the Task Force for the
management of valvular heart disease of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic
Surgery (EACTS). European Heart Journal 2021;43 :561-632.
[4] Isaacs AJ, Shuhaiber J, Salemi A, Isom OW, Sedrakyan A. National
trends in utilization and in-hospital outcomes of mechanical versus
bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg
2015;149 :1262-9.
[5] Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, Mirza A, Loardi
C, May MA et al. Very long-term outcomes of the
Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg
2015;99 :831-7.
[6] Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE,
Sabik JF et al. Long-term durability of bioprosthetic aortic
valves: implications from 12,569 implants. Ann Thorac Surg
2015;99 :1239-47.
[7] Anselmi A, Ruggieri VG, Belhaj Soulami R, Flécher E, Langanay T,
Corbineau H et al. Hemodynamic results and mid-term follow-up of
850 19 to 23 mm Perimount Magna Ease valves. Thorac Cardiovasc Surg
2019;67 :274-81.
[8] Banbury MK, Cosgrove DM, 3rd, Thomas JD, Blackstone EH,
Rajeswaran J, Okies JE et al. Hemodynamic stability during 17
years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann
Thorac Surg 2002;73 :1460-5.
[9] Carpentier A. From valvular xenograft to valvular bioprosthesis
(1965-1977). Med Instrum 1977;11 :98-101.
[10] Carpentier A, Dubost C, Lane E, Nashef A, Carpentier S, Relland
J et al. Continuing improvements in valvular bioprostheses. J
Thorac Cardiovasc Surg 1982;83 :27-42.
[11] Thorp SD, Khazaal J, Yu G, Parker JL, Timek TA. Magna ease
bioprosthetic aortic valve: mid-term haemodynamic outcomes in 1126
patients. Interact Cardiovasc Thorac Surg 2021;32 :839-45.
[12] Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH,
Grunkemeier GL et al. Guidelines for reporting mortality and
morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg
2008;135 :732-8.
[13] Piperata A, Fiocco A, Cavicchiolo A, Ponzoni M, Pesce R,
Gemelli M et al. Carpentier-Edwards Magna Ease bioprosthesis: a
multicentre clinical experience and 12-year durability. Eur J
Cardiothorac Surg 2022;61 :888-96.
[14] Goldman S, Cheung A, Bavaria JE, Petracek MR, Groh MA, Schaff
HV. Midterm, multicenter clinical and hemodynamic results for the
Trifecta aortic pericardial valve. J Thorac Cardiovasc Surg
2017;153 :561-9 e2.
[15] Lehmann S, Jawad K, Dieterlen MT, Hoyer A, Garbade J,
Davierwala P et al. Durability and clinical experience using a
bovine pericardial prosthetic aortic valve. J Thorac Cardiovasc Surg
2021;161 :1742-9.
[16] Biancari F, Valtola A, Juvonen T, Husso A, Dahlbacka S, Laakso
T et al. Trifecta versus PERIMOUNT Magna Ease aortic valve
prostheses. Ann Thorac Surg 2020;110 :879-88.
[17] Yang B, Makkinejad A, Fukuhara S, Clemence J, Jr., Farhat L,
Malik A et al. Stentless Versus Stented Aortic Valve Replacement
for Aortic Stenosis. Ann Thorac Surg 2022.
[18] Yount KW, Hawkins RB, Mehaffey JH, Teman NR, Yarboro LT, Kern
JA et al. Aortic valve biologic protheses: A cohort comparison of
premature valve failure. J Card Surg 2022.
[19] Axtell AL, Chang DC, Melnitchouk S, Jassar AS, Tolis G,
Villavicencio MA et al. Early structural valve deterioration and
reoperation associated with the mitroflow aortic valve. J Card Surg
2018;33 :778-86.
[20] Yanagawa B, Tam DY, Hong K, Mazine A, Bagai A, Shahbaz NKet al. Magna Ease versus Trifecta early hemodynamics: a
systematic review and meta-analysis. Innovations (Phila)
2018;13 :267-72.
[21] Yongue C, Lopez DC, Soltesz EG, Roselli EE, Bakaeen FG,
Gillinov AM et al. Durability and performance of 2298 Trifecta
aortic valve prostheses: a propensity-matched analysis. Ann Thorac Surg
2021;111 :1198-205.
[22] Forcillo J, Pellerin M, Perrault LP, Cartier R, Bouchard D,
Demers P et al. Carpentier-Edwards pericardial valve in the
aortic position: 25-years experience. Ann Thorac Surg
2013;96 :486-93.
[23] Kilic A, Sultan I, Navid F, Aranda-Michel E, Chu D, Thoma Fet al. Trifecta aortic bioprosthesis: midterm results in 1,953
patients from a single center. Ann Thorac Surg
2019;107 :1356-62.
[24] Bartus K, Litwinowicz R, Bilewska A, Stapor M, Bochenek M,
Rozanski J et al. Final 5-year outcomes following aortic valve
replacement with a RESILIA™ tissue bioprosthesis. Eur J Cardiothorac
Surg 2021;59 :434-41.
[25] Johnston DR, Griffith BP, Puskas JD, Bavaria JE, Svensson LG,
Investigators CT. Intermediate-term outcomes of aortic valve replacement
using a bioprosthesis with a novel tissue. J Thorac Cardiovasc Surg
2020;162 :1478-85.